DOCSLIB.ORG

Endocrinology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

THE AMERICAN BOARD OF PEDIATRICS® CONTENT OUTLINE Pediatric Endocrinology Subspecialty In-Training, Certification, and Maintenance of Certification (MOC) Examinations INTRODUCTION This document was prepared by the American Board of Pediatrics Subboard of Pediatric Endocrinology for the purpose of developing in-training, certification, and maintenance of certification examinations. The outline defines the body of knowledge from which the Subboard samples to prepare its examinations. The content specification statements located under each category of the outline are used by item writers to develop questions for the examinations; they broadly address the specific elements of knowledge within each section of the outline. Pediatric Endocrinology Each Pediatric Endocrinology exam is built to the same specifications, also known as the blueprint. This blueprint is used to ensure that, for the initial certification and in-training exams, each exam measures the same depth and breadth of content knowledge. Similarly, the blueprint ensures that the same is true for each Maintenance of Certification exam form. The table below shows the percentage of questions from each of the content domains that will appear on an exam. Please note that the percentages are approximate; actual content may vary. Initial Maintenance Certificatio of Content Categories n and Certification In-Training (MOC) 1. Carbohydrate Metabolism 16% 16% 2. Bone and Mineral Metabolism 8% 8% Thyroid Hormones (Thyroxine 3. [T4] and Triiodothyronine [T3]) 13% 14% 4. Adrenal Disorders 12% 12% 5. Pituitary/Hypothalamus 10% 10% 6. Growth 12% 14% 7. Reproductive Endocrine System 12% 12% 8. Other Hormones 3% 3% 9. Lipoproteins and Lipids 3% 3% Multiple endocrine neoplasia and 10. polyglandular autoimmune disease 2% 2% 11. Methods and Biological Principles 4% 2% 12. Core Knowledge in Scholarly Activities 5% 4% Endocrinology 1. Carbohydrate Metabolism A. Integrated hormone effects on metabolism 1. Physiology a. Know the sources of glucose from: digestion and absorption of dietary carbohydrates; endogenous release of glucose from the liver b. Know the enzyme systems (glycogenolysis, glycogen synthesis, glycolysis, gluconeogenesis, tricarboxylic acid cycle, and pentose phosphate shunt) involved in the storage, oxidation, and production of glucose c. Understand the processes and regulation of nutrient and substrate metabolism in the fasted and fed states with regard to glycogen, glucose, fatty acids, ketone bodies, amino acid, and protein metabolism d. Know effects of insulin on protein synthesis and proteolysis; lipolysis and ketogenesis; glucose production and utilization e. Understand the mechanisms of action of cortisol, growth hormone (GH), epinephrine, and somatostatin on carbohydrate, fat, and protein metabolism f. Be familiar with the endocrine and metabolic responses to fasting g. Know the effects of lipotoxicity and glucotoxicity on beta cell function and insulin resistance 2. Homeostasis a. Know the criteria for a normal blood glucose concentration in children, and adolescents, and the definitions of biochemical hyperglycemia and hypoglycemia at these ages b. Know the rate of glucose production (expressed as glucose infusion rate) in normal neonates, children, and adolescents, and the factors which regulate it c. Know the duration of time glycogen stores and gluconeogenesis can maintain normal blood glucose concentrations in normal neonates, children and adolescents B. Insulin 1. Physiology a. Ontogeny/embryology 1. Know the genes that are responsible for pancreatic development b. Synthesis/processing/storage 1. Know biochemistry of insulin biosynthesis and post-translational processing 2. Know the structural homology of insulin-like growth factor (and other growth factors) with insulin c. Secretion 1. Understand physiologic regulation of insulin secretion including the effects of blood glucose, amino acids, glucagon, adrenergic mechanisms, gastric inhibitory peptide (GIP), and somatostatin 2. Know the importance of the sulfonylurea receptor, chromium picolinate, the potassium channel, and the role of calcium flux in insulin secretion 3. Understand the role of glucokinase in insulin secretion 4. Know the interactions of medications and other exogenous substances that regulate insulin secretion with beta cell receptors and channels d. Receptor/action 1. Tissue/organ specific a. Know the plasma membrane location, structure, and function of the insulin receptor b. Know the role or lack thereof of insulin on glucose transporters in different tissues c. Know that different glucose transporters are expressed in different tissues d. Know the relationship of the structures of IGF-I and insulin receptors and the related membrane molecules e. Understand insulin receptor signaling mechanisms 2. Pathology a. Insulin deficiency with hyperglycemia 1. Type 1 diabetes a. Pathophysiology (classification/etiology) 1. Know the association of HLA and DR loci in the etiology of type 1 diabetes 2. Recognize histologic appearance of islets early and late in the course of type 1 diabetes with preferential destruction of beta cells and late persistence of alpha and delta cells 3. Know the current concepts of the role of autoimmunity including cell- mediated immunity and cytoplasmic and surface autoantibodies and insulin autoantibodies in the pathogenesis and prediction of type 1 diabetes 4. Know the rationale for the use of immunomodulating agents for the treatment of early type 1 diabetes 5. Know the prevalence of glutamic acid decarboxylase, islet cell, and insulin antibodies in recent-onset type 1 diabetes and in individuals of various ages b. Epidemiology and clinical manifestations 1. Know the different prevalence rates of type 1 diabetes in people of different ethnicities 2. Know the risk of type 1 diabetes development in identical twins, other siblings, offspring, and parents of patients who have type 1 diabetes 3. Understand the clinical differentiation of ketoacidosis from other causes of altered states of consciousness, such as hypoglycemia and nonketotic hyperosmolar coma, in diabetes mellitus 4. Understand the pathogenesis of ketoacidosis and disturbances in body fluid, electrolytes, substrates, and acid-base balance (pH, O2 dissociation), and the significance of relevant laboratory findings in type 1 diabetes 5. Recognize the mechanism, presentation, and natural history of neonatal diabetes c. Diagnosis 1. Recognize the stages of clinical development of type 1 diabetes with progressive carbohydrate intolerance, and the pathophysiology of the polyuria, polydipsia, weight loss, and fatigue d. Treatment of diabetic ketoacidosis 1. Know the methods, rationale, consequences, and principles of administration of insulin (bolus and IV infusion) in the treatment of diabetic ketoacidosis 2. Know the rationale and strategy for monitoring blood glucose, serum electrolytes, acid-base balance and ketone concentrations in the management of patients with diabetic ketoacidosis 3. Know when and how to change to subcutaneous insulin and oral intake in patients recovering from diabetic ketoacidosis 4. Know the complications (cerebral edema, hyperkalemia, hypokalemia, renal failure, hyperchloremia, hypoglycemia, persistent hyperglycemia, thrombosis, and/or ketonemia), pathophysiology, clinical manifestations and management in the treatment of diabetic ketoacidosis 5. Recognize that repeated episodes of ketoacidosis in a child or adolescent are most likely a result of failure to administer insulin regularly rather than dietary indiscretions or infectious illness 6. Know the methods, rationale, consequences, and principles of administration of fluid and electrolytes in the treatment of diabetic ketoacidosis 7. Know the methods, rationale, consequences, and principles of administration of glucose in the treatment of diabetic ketoacidosis 8. Know the risk factors for cerebral edema in diabetic ketoacidosis e. Daily management 1. Know the formulations and action profiles of rapid, short, intermediate, and long-acting insulins 2. Recognize blood glucose values requiring insulin dose adjustments in patients with diabetes using home glucose monitoring 3. Understand the effects of meals, exercise, illness, trauma, and surgery on blood glucose concentration and insulin requirements of patients who have diabetes 4. Know the use and significance of glycosylated hemoglobin and factors other than blood glucose concentration (eg, hemolytic anemia) that affect or alter its value in the management of patients with diabetes 5. Know the carbohydrate content of common foods 6. Know how to calculate an insulin-to-carbohydrate ratio for determination of insulin dosing for patients with diabetes 7. Be able to identify patients with type 1 diabetes who will succeed with insulin infusion pump therapy and know the steps required to prepare a patient for insulin pump therapy 8. Know how to calculate an initial basal and bolus insulin dose for a patient beginning insulin pump therapy 9. Know the pros and cons of intensification of diabetes management with both multiple daily insulin doses and with continuous subcutaneous insulin infusion therapy 10. Know how to make insulin dose adjustments in patients with type 1 diabetes using home glucose monitoring 11. Understand the rationale and appropriate use of continuous glucose monitoring devices in children with type 1 diabetes, including clinical indications and limits 12. Know how to convert insulin dose from intermediate/rapid-acting insulin regimens to basal-bolus regimens using
Recommended publications
  • PL5 Year Pediatric Endocrinology Goals and Objectives for Clinical Service Months

    PL5 Year Pediatric Endocrinology Goals and Objectives for Clinical Service Months

    University of Texas San Antonio Pediatric Endocrinology Fellowship Jane L. Lynch, MD, PD Elia Escaname MD, APD Fellowship Director 2020 PL 5 Year Pediatric Endocrinology Goals and Objectives for Clinical Service Months The goals for the clinical rotations at the Texas Diabetes Institute are to develop the knowledge, attitudes and skills necessary to evaluate, diagnose and manage endocrine conditions in pediatric patients in a manner commensurate with level of training. July 2020 Page 1 COMPETENCIES: PATIENT CARE: Develop proficiency in the care of infants, children, and adolescents with endocrine disorders. Practice the necessary skills for good patient care 1A Goal: Develop proficiency in respectfully gathering essential information through review of pertinent records, interviewing patients and caregivers/family members with particular attention to relevant history, systematic medical assessment and physical exam on a patient with concerns of an endocrine disorder. These skills apply to outpatient, inpatient and research patients. Objectives • Obtain appropriate history and perform a physical exam for patients referred with the following endocrine conditions • Generate a problem list and create an assessment of the patient using up to date nomenclature • Suggest and interpret appropriate laboratory tests and summarize pertinent positive and negative findings with a differential diagnosis. • Develop proficiency in developing a treatment plan based on the endocrine diagnosis • Carry out the care plan with follow-up clinic visits, lab study interpretation and timely review of the results with the attending endocrine physician Endocrine Conditions: 1. Short stature, including constitutional delay 2. Disorders of anterior pituitary hormone physiology, including growth hormone deficiency 3. Disorders of posterior pituitary hormone physiology, including diabetes insipidus 4.
  • Endocrinology Resident Profile Jill Trinacty

    Endocrinology Resident Profile Jill Trinacty

    Endocrinology Resident Profile Jill Trinacty July 2017 About me My name is Jill Trinacty, and I was raised in Berwick, Nova Scotia. I went completed my BSc. (Honours) at Saint Francis Xavier University in Antigonish, Nova Scotia. I spent a year as the Active Living Coordinator with the Town of Kentville then completed my MD at Dalhousie University. I moved to Ottawa, Ontario in 2013 for my residency in Internal Medicine at the University of Ottawa and am currently a PGY-5 in Endocrinology and Metabolism. Why I chose General Endocrinology In medical school I became interested in almost every area of medicine, but ultimately applied to internal medicine for a number of reasons. I have always been interested in Endocrinology, specifically diabetes. Diabetes affects so many people in our communities and can have significant morbidity and mortality. I liked the detail of internal medicine and the complexity of patients. Having some previous experience in public health, I knew that I wanted a career that would allow me to discuss lifestyle changes as an aspect of therapy – specifically nutrition and physical activity. I also wanted a career that would allow for work/life balance. Seeing the day-to-day lifestyle of each internal medicine subspecialty confirmed that Endocrinology was the right fit for me. Clinical Life What does a typical day of clinical duties involve? This is an example of my typical daily and weekly schedule: Endocrinology – A typical day 7:30 – 8:00 Clerical work / Chief resident duties. Review emails, follow up on patient results, approve vacation requests, make call schedule.
  • Thyroid Function Tests (Tfts) | Memorial Sloan Kettering Cancer Center

    Thyroid Function Tests (Tfts) | Memorial Sloan Kettering Cancer Center

    PATIENT & CAREGIVER EDUCATION Thyroid Function Tests (TFTs) This information explains thyroid function tests (TFTs). Thyroid function tests are blood tests that let your doctor see if you have the right amount of thyroid hormone in your blood. Thyroid Stimulating Hormone (TSH) Thyroid stimulating hormone (TSH) is made and released by a gland in your brain. This hormone stimulates your thyroid to work. TSH levels The level of TSH in your blood shows if your thyroid is too active or not active enough. If you don’t have a thyroid, your TSH level tells your doctor if you’re getting the right dose of thyroid hormone replacement medication. The normal TSH range differs slightly from one lab to another. At Memorial Sloan Kettering (MSK), the normal range is 0.55 milli-international units per liter (mIU/L) to 4.78 mIU/L. Depending on the type of thyroid cancer you have, your doctor may want your TSH to be below the normal range. Talk to your doctor about your TSH levels. You can write down your TSH goal below. Your TSH goal is: _______________________ If your TSH level is low, you’re in a state of hyperthyroidism. This means your thyroid function is too active. If your TSH level is high, you’re in a state of hypothyroidism. This means your thyroid function isn’t active enough. Thyroid Function Tests (TFTs) 1/3 In people without thyroid cancer, the goal is to keep their TSH level within the normal range. In some people with thyroid cancer, the goal is to keep their TSH level below the normal range for the first couple of years after being diagnosed.
  • Transferrin Variants and Conjugates

    Transferrin Variants and Conjugates

    (19) TZZ Z ¥ T (11) EP 2 604 623 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 19.06.2013 Bulletin 2013/25 C07K 14/79 (2006.01) A61K 47/48 (2006.01) A61K 38/40 (2006.01) C12N 5/10 (2006.01) (21) Application number: 12189421.6 (22) Date of filing: 08.08.2008 (84) Designated Contracting States: • Friis, Esben Peter AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 2730 Herlev (DK) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • Hay, Joanna RO SE SI SK TR Nottingham, Nottinghamshire NG2 6QW (GB) • Finnis, Christopher John Arthur (30) Priority: 08.08.2007 EP 07114012 Nottingham, Nottinghamshire NG7 1JB (GB) 02.04.2008 EP 08153938 (74) Representative: Williams, Rachel Clare (62) Document number(s) of the earlier application(s) in Novozymes Biopharma UK Limited accordance with Art. 76 EPC: Castle Court 08787067.1 / 2 201 036 59 Castle Boulevard Nottingham (71) Applicant: Novozymes Biopharma DK A/S Nottinghamshire NG7 1FD (GB) 2880 Bagsvaerd (DK) Remarks: (72) Inventors: This application was filed on 22-10-2012 as a • Sleep, Darrell divisional application to the application mentioned Nottingham, Nottinghamshire NG2 5DS (GB) under INID code 62. (54) Transferrin variants and conjugates (57) Based on the three-dimensional structure of "thiotransferrin"). The variant polypeptide may be conju- transferrin, the inventors have designed variant polypep- gated through the sulphur atom of the Cysteine residue tides (muteins) which have one or more Cysteine resi- to a bioactive compound. dues with a free thiol group (hereinafter referred to as EP 2 604 623 A2 Printed by Jouve, 75001 PARIS (FR) EP 2 604 623 A2 Description Reference to sequence listing 5 [0001] This application contains a Sequence Listing in computer readable form.
  • Sp — 001 Sd9900033

    Sp — 001 Sd9900033

    -SP — 001 SD9900033 to ei Mansour El Tahir Farah Supervisor: Prof. El Daw Mukhtar Co-supervisor: Assoc, Prof. El Tom Sirag El Bin Khartoum -1997 r 30-36 ,• v -\ :.-- DISCLAIMER Portions of this document may be illegible in electronic image products, Images are produced from the best available original document. Contents Declaration I Acknowledgement , II Abstract English Ill Abstract Arabic V List of Abbreviations VII List of Tables VIII List of Figures X Chapter I Introduction and Literature Review 1 Objectives of the Study 40 Chapter II Patients and Methods 41 Chapter III Results 45 Chapter IV Discussion ; 75 Conclusion 82 Recommendations 84 References 85 Appendices The Questionnaire 101 I would like to declare that all the research work was done by myself. I consulted all the literature included in this study . This work has not been submitted to any other university . The information in this thesis has not been published elsewhere. ifp I would like to express my deep gratitude to my supervisor Professor El Daw Mukhtar whose continued enthusiasm and support had guided and encouraged me throughout the study period . This work would not been possible without the benefit of his generous help and leading advices . I am greatly indebted to Dr. El Tom Sirag El Din for his valuable comments and leading advices , helping me alot during preparation of this thesis . My great thanks to the staff in the diagnostic and research laboratory centre , who gave every possible help during my work . I am greatly appreciating the help that had been provided by all doctors technicians and patients .
  • Abstracts from the 9Th Biennial Scientific Meeting of The

    Abstracts from the 9Th Biennial Scientific Meeting of The

    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
  • Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in A

    Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in A

    Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in a novel member of the chromodomain gene family cause CHARGE syndrome. L.E.L.M. Vissers1, C.M.A. van Ravenswaaij1, R. Admiraal2, J.A. Hurst3, B.B.A. de Vries1, I.M. Janssen1, W.A. van der Vliet1, E.H.L.P.G. Huys1, P.J. de Jong4, B.C.J. Hamel1, E.F.P.M. Schoenmakers1, H.G. Brunner1, A. Geurts van Kessel1, J.A. Veltman1. 1) Dept Human Genetics, UMC Nijmegen, Nijmegen, Netherlands; 2) Dept Otorhinolaryngology, UMC Nijmegen, Nijmegen, Netherlands; 3) Dept Clinical Genetics, The Churchill Hospital, Oxford, United Kingdom; 4) Children's Hospital Oakland Research Institute, BACPAC Resources, Oakland, CA. CHARGE association denotes the non-random occurrence of ocular coloboma, heart defects, choanal atresia, retarded growth and development, genital hypoplasia, ear anomalies and deafness (OMIM #214800). Almost all patients with CHARGE association are sporadic and its cause was unknown. We and others hypothesized that CHARGE association is due to a genomic microdeletion or to a mutation in a gene affecting early embryonic development. In this study array- based comparative genomic hybridization (array CGH) was used to screen patients with CHARGE association for submicroscopic DNA copy number alterations. De novo overlapping microdeletions in 8q12 were identified in two patients on a genome-wide 1 Mb resolution BAC array. A 2.3 Mb region of deletion overlap was defined using a tiling resolution chromosome 8 microarray. Sequence analysis of genes residing within this critical region revealed mutations in the CHD7 gene in 10 of the 17 CHARGE patients without microdeletions, including 7 heterozygous stop-codon mutations.
  • Searching for Novel Peptide Hormones in the Human Genome Olivier Mirabeau

    Searching for Novel Peptide Hormones in the Human Genome Olivier Mirabeau

    Searching for novel peptide hormones in the human genome Olivier Mirabeau To cite this version: Olivier Mirabeau. Searching for novel peptide hormones in the human genome. Life Sciences [q-bio]. Université Montpellier II - Sciences et Techniques du Languedoc, 2008. English. tel-00340710 HAL Id: tel-00340710 https://tel.archives-ouvertes.fr/tel-00340710 Submitted on 21 Nov 2008 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE MONTPELLIER II SCIENCES ET TECHNIQUES DU LANGUEDOC THESE pour obtenir le grade de DOCTEUR DE L'UNIVERSITE MONTPELLIER II Discipline : Biologie Informatique Ecole Doctorale : Sciences chimiques et biologiques pour la santé Formation doctorale : Biologie-Santé Recherche de nouvelles hormones peptidiques codées par le génome humain par Olivier Mirabeau présentée et soutenue publiquement le 30 janvier 2008 JURY M. Hubert Vaudry Rapporteur M. Jean-Philippe Vert Rapporteur Mme Nadia Rosenthal Examinatrice M. Jean Martinez Président M. Olivier Gascuel Directeur M. Cornelius Gross Examinateur Résumé Résumé Cette thèse porte sur la découverte de gènes humains non caractérisés codant pour des précurseurs à hormones peptidiques. Les hormones peptidiques (PH) ont un rôle important dans la plupart des processus physiologiques du corps humain.
  • Endocrinology

    Endocrinology

    Endocrinology INTRODUCTION Endocrinology 1. Endocrinology is the study of the endocrine system secretions and their role at target cells within the body and nervous system are the major contributors to the flow of information between different cells and tissues. 2. Two systems maintain Homeostasis a. b 3. Maintain a complicated relationship 4. Hormones 1. The endocrine system uses hormones (chemical messengers/neurotransmitters) to convey information between different tissues. 2. Transport via the bloodstream to target cells within the body. It is here they bind to receptors on the cell surface. 3. Non-nutritive Endocrine System- Consists of a variety of glands working together. 1. Paracrine Effect (CHEMICAL) Endocrinology Spring 2013 Page 1 a. Autocrine Effect i. Hormones released by cells that act on the membrane receptor ii. When a hormone is released by a cell and acts on the receptors located WITHIN the same cell. Endocrine Secretions: 1. Secretions secreted Exocrine Secretion: 1. Secretion which come from a gland 2. The secretion will be released into a specific location Nervous System vs tHe Endocrine System 1. Nervous System a. Neurons b. Homeostatic control of the body achieved in conjunction with the endocrine system c. Maintain d. This system will have direct contact with the cells to be affected e. Composed of both the somatic and autonomic systems (sympathetic and parasympathetic) Endocrinology Spring 2013 Page 2 2. Endocrine System a. b. c. 3. Neuroendocrine: a. These are specialized neurons that release chemicals that travel through the vascular system and interact with target tissue. b. Hypothalamus à posterior pituitary gland History of tHe Endocrine System Bertold (1849)-FATHER OF ENDOCRINOLOGY 1.
  • Versus High-Chloride-Containing Hypertonic Solution for the Treatment

    Versus High-Chloride-Containing Hypertonic Solution for the Treatment

    Sadan et al. Journal of Intensive Care (2020) 8:32 https://doi.org/10.1186/s40560-020-00449-0 RESEARCH Open Access Low-chloride- versus high-chloride- containing hypertonic solution for the treatment of subarachnoid hemorrhage– related complications: The ACETatE (A low ChloriE hyperTonic solution for brain Edema) randomized trial Ofer Sadan1*, Kai Singbartl2, Jacqueline Kraft1, Joao McONeil Plancher1, Alexander C. M. Greven3, Prem Kandiah1, Cederic Pimentel1, C. L. Hall1, Alexander Papangelou4, William H. Asbury5, John J. Hanfelt6 and Owen Samuels1 Abstract Background: Recent reports have demonstrated that among patients with subarachnoid hemorrhage (SAH) treated with hypertonic NaCl, resultant hyperchloremia has been associated with the development of acute kidney injury (AKI). We report a trial comparing the effect of two hypertonic solutions with different chloride contents on the resultant serum chloride concentrations in SAH patients, with a primary outcome aimed at limiting chloride elevation. Methods: A low ChloridE hyperTonic solution for brain Edema (ACETatE) trial is a single-center, double-blinded, double-dummy, randomized pilot trial comparing bolus infusions of 23.4% NaCl and 16.4% NaCl/Na-acetate for the treatment of cerebral edema in patients with SAH. Randomization occurred when patients developed hyperchloremia (serum Cl− ≥ 109 mmol/L) and required hyperosmolar treatment. Results: We enrolled 59 patients, of which 32 developed hyperchloremia and required hyperosmolar treatment. 15 patients were randomized to the 23.4% NaCl group, and 17 patients were randomized to the 16.4% NaCl/Na- acetate group. Although serum chloride levels increased similarly in both groups, the NaCl/Acetate group showed a significantly lower Cl− load at the end of the study period (978mEq vs.
  • Chronic Fatigue: Is It Endocrinology?

    Chronic Fatigue: Is It Endocrinology?

    I ORIGINAL PAPERS Chronic fatigue: is it endocrinology? Kate M Evans, Daniel E Flanagan and Terence J Wilkin Kate M Evans ABSTRACT – Fatigue and stress-related illnesses imal physical signs where initial investigations are MRCP, Consultant often become diagnoses of exclusion after exten- normal. It is possible to reassure the individual that Physician sive investigation. ‘Tired all the time’ is a frequent there is no significant disease at that point but there Daniel E reason for referral to the endocrine clinic, the are no clear data to address the question of whether Flanagan implicit question being – is there a subtle overt pathology will develop in the future. This paper FRCP, Consultant endocrine pathology contributing to the patient’s reports audit findings for a cohort of patients seen Physician symptoms? Often initial assessment suggests not in an endocrinology clinic with fatigue, including but there are no clear data to address the ques- Terence J Wilkin outcome data at five or more years later. FRCP, Professor of tion of whether overt pathology will develop in the Medicine future. This study observed outcomes after five Subjects and methods years in 101 consecutive and unselected referrals Department of to secondary care for ‘fatigue?cause’, where initial Consecutive and unselected referrals from primary Endocrinology and assessment did not suggest treatable endocrine care to the endocrinology service over a four-year Metabolism, Peninsula Medical pathology. The findings suggest that the clinical period (1995–99) were identified from the clinic School, Plymouth diagnosis of fatigue, based on history and tests to database. Referrals were included in the dataset if the and Derriford exclude anaemia, hypothyroidism and diabetes, is primary reason for referral or primary symptom was Hospital, Plymouth secure: these patients do not subsequently fatigue.
  • Clinical Physiology Aspects of Chloremia in Fluid Therapy: a Systematic Review David Astapenko1,2* , Pavel Navratil2,3, Jiri Pouska4,5 and Vladimir Cerny1,2,6,7,8,9

    Clinical Physiology Aspects of Chloremia in Fluid Therapy: a Systematic Review David Astapenko1,2* , Pavel Navratil2,3, Jiri Pouska4,5 and Vladimir Cerny1,2,6,7,8,9

    Astapenko et al. Perioperative Medicine (2020) 9:40 https://doi.org/10.1186/s13741-020-00171-3 REVIEW Open Access Clinical physiology aspects of chloremia in fluid therapy: a systematic review David Astapenko1,2* , Pavel Navratil2,3, Jiri Pouska4,5 and Vladimir Cerny1,2,6,7,8,9 Abstract Background: This systematic review discusses a clinical physiology aspect of chloride in fluid therapy. Crystalloid solutions are one of the most widely used remedies. While generally used in medicine for almost 190 years, studies focused largely on their safety have only been published since the new millennium. The most widely used solution, normal saline, is most often referred to in this context. Its excessive administration results in hyperchloremic metabolic acidosis with other consequences, including higher mortality rates. Methods: Original papers and review articles eligible for developing the present paper were identified by searching online in the electronic MEDLINE database. The keywords searched for included hyperchloremia, hypochloremia, and compound words containing the word “chloride,” infusion therapy, metabolic acidosis, renal failure, and review. Results: A total of 21,758 papers published before 31 May 2020 were identified; of this number, 630 duplicates were removed from the list. Upon excluding articles based on their title or abstract, 1850 papers were screened, of which 63 full-text articles were assessed. Conclusions: According to the latest medical concepts, dyschloremia (both hyperchloremia and hypochloremia) represents a factor indisputably having a negative effect on selected variables of clinical outcome. As infusion therapy can significantly impact chloride homeostasis of the body, the choice of infusion solutions should always take into account the potentially adverse impact of chloride content on chloremia and organ function.